GENOMICTREE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22,100 KRW | -0.67% |
|
-3.07% | +7.28% |
| 2023 | Genomictree Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2022 | Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022. | CI |
| Sales 2022 | 29.87B 21.89M 1.75B | Sales 2023 | 3.42B 2.51M 200M | Capitalization | 487B 357M 28.48B |
|---|---|---|---|---|---|
| Net income 2022 | -6.63B -4.86M -388M | Net income 2023 | -8.76B -6.42M -512M | EV / Sales 2022 | 3.22 x |
| Net cash position 2022 | 85.43B 62.62M 5B | Net cash position 2023 | 91.31B 66.93M 5.34B | EV / Sales 2023 | 116 x |
| P/E ratio 2022 |
-27.8
x | P/E ratio 2023 |
-45.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.97% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.67% | ||
| 1 week | -3.07% | ||
| Current month | -0.23% | ||
| 1 month | -0.23% | ||
| 3 months | +17.62% | ||
| 6 months | +43.79% | ||
| Current year | +7.28% |
1 week
21 950.00
23 850.00
1 month
19 550.0026 150.00
Current year
16 740.0027 950.00
1 year
11 600.0030 950.00
3 years
8 310.0030 950.00
5 years
8 310.0039 700.00
10 years
4 000.0039 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chi-Wang Yoon
FOU | Founder | 62 | 05/10/00 |
Sung-Whan An
FOU | Founder | 63 | 05/10/00 |
Hong Sun Lee
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Whan An
FOU | Founder | 63 | 05/10/00 |
Chi-Wang Yoon
FOU | Founder | 62 | 05/10/00 |
Tae-Jeong Oh
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 21,150 | -4.30% | 477,128 |
| 30/04/24 | 22,100 | -0.67% | 241,068 |
| 29/04/24 | 22,250 | -0.45% | 188,180 |
| 26/04/24 | 22,350 | -1.97% | 255,989 |
| 25/04/24 | 22,800 | -3.39% | 216,843 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Genomictree Inc. is a Korea-based company mainly engaged in the genomic analysis. The Company is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.28% | 377M | |
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B |
- Stock Market
- Equities
- A228760 Stock
